A Plus Biotechnology Co

A Plus Biotechnology Co EBIT

The EBIT of A Plus Biotechnology Co (6918.TWO) as of Oct 29, 2026 is 182.46 M TWD. In the previous year, EBIT was 167.54 M TWD — a change of 8.90% (higher).

EBIT

182.46 MTWD

YoY

8.90%

Last updated:

In 2024, A Plus Biotechnology Co's EBIT was 182.46 M TWD, a 8.90% increase from the 167.54 M TWD EBIT recorded in the previous year.

The A Plus Biotechnology Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
41.75 M TWD
Jan 1, 2020
42.53 M TWD
Jan 1, 2021
46.74 M TWD
Jan 1, 2022
66.98 M TWD
Jan 1, 2023
167.54 M TWD
Jan 1, 2024
182.46 M TWD
The A Plus Biotechnology Co EBIT history
YEAREBITYoY
182.46 MTWD+8.90%
167.54 MTWD+150.15%
66.98 MTWD+43.29%
46.74 MTWD+9.91%
42.53 MTWD+1.86%
41.75 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

A Plus Biotechnology Co Revenue

A Plus Biotechnology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
473.98 M TWD
41.75 M TWD
31.18 M TWD
Jan 1, 2020
503.29 M TWD
42.53 M TWD
36.06 M TWD
Jan 1, 2021
541.85 M TWD
46.74 M TWD
32.94 M TWD
Jan 1, 2022
615.48 M TWD
66.98 M TWD
45.70 M TWD
Jan 1, 2023
675.05 M TWD
167.54 M TWD
31.16 M TWD
Jan 1, 2024
769.59 M TWD
182.46 M TWD
151.06 M TWD

A Plus Biotechnology Co Margins

A Plus Biotechnology Co stock margins

The A Plus Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of A Plus Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for A Plus Biotechnology Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
72.27 %
8.81 %
6.58 %
Jan 1, 2020
63.17 %
8.45 %
7.17 %
Jan 1, 2021
63.93 %
8.63 %
6.08 %
Jan 1, 2022
60.75 %
10.88 %
7.43 %
Jan 1, 2023
68.24 %
24.82 %
4.62 %
Jan 1, 2024
69.49 %
23.71 %
19.63 %

A Plus Biotechnology Co Stock analysis

What does A Plus Biotechnology Co do? A Plus Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of orthopedic medical equipment. The company offers trauma products such as orthopedic internal fixation bone plates, bone nails, and external fixators for stable fracture fixation. Orthopedic products include knee arthritis correction systems and hallux valgus correction systems, while spinal products feature spinal fixation systems and spinal intervertebral fusion devices. Proxy products encompass artificial bone replacement and cartilage repair solutions. The company primarily sells its products domestically in Taiwan and exports to mainland China, Asia, the United States, and Africa, serving healthcare providers and medical institutions across these regions. Trauma products are utilized for stabilizing fractures across various bone types and locations, with applications including intramedullary nails and cables. Orthopedic products assist in precise correction and fixation, such as additive manufacturing surgical guide plates. Spinal products support spinal fixation and intervertebral height maintenance through spinal intervertebral fusion devices. Proxy products like cell therapy and artificial bone replacement cater to tissue repair and regeneration needs. The company's export markets include mainland China, Asia, the United States, and Africa, with domestic sales in Taiwan forming a significant segment. The company's product portfolio includes orthopedic internal fixation bone plates, bone nails, and spinal fixation systems, which are sold to medical institutions and healthcare providers. Trauma products such as external fixators and intramedullary nails are distributed to hospitals and clinics for fracture treatment. Orthopedic products like knee arthritis correction systems are targeted at specialized surgical procedures. Spinal products including intervertebral fusion devices are used in spinal surgeries. Proxy products such as cartilage repair solutions and cell therapy are supplied to medical facilities requiring tissue regeneration treatments. A Plus Biotechnology Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing A Plus Biotechnology Co's EBIT

A Plus Biotechnology Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of A Plus Biotechnology Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

A Plus Biotechnology Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in A Plus Biotechnology Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about A Plus Biotechnology Co stock

EBIT of A Plus Biotechnology Co is 182.46 M TWD in 2024.

EBIT of A Plus Biotechnology Co changed from 167.54 M TWD to 182.46 M TWD, representing a 8.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT A Plus Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's A Plus Biotechnology Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — A Plus Biotechnology Co

All Key Metrics — A Plus Biotechnology Co